ATE202938T1 - Methode zur behandlung des systemischen lupus erythematodes - Google Patents

Methode zur behandlung des systemischen lupus erythematodes

Info

Publication number
ATE202938T1
ATE202938T1 AT92907399T AT92907399T ATE202938T1 AT E202938 T1 ATE202938 T1 AT E202938T1 AT 92907399 T AT92907399 T AT 92907399T AT 92907399 T AT92907399 T AT 92907399T AT E202938 T1 ATE202938 T1 AT E202938T1
Authority
AT
Austria
Prior art keywords
systemic lupus
death
treating systemic
lupus erythema
erythema
Prior art date
Application number
AT92907399T
Other languages
English (en)
Inventor
Linda Marie Warner
Laurel Moore Adams
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of ATE202938T1 publication Critical patent/ATE202938T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
AT92907399T 1991-02-22 1992-02-21 Methode zur behandlung des systemischen lupus erythematodes ATE202938T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/660,470 US5078999A (en) 1991-02-22 1991-02-22 Method of treating systemic lupus erythematosus
PCT/US1992/001399 WO1992014477A1 (en) 1991-02-22 1992-02-21 Method of treating systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
ATE202938T1 true ATE202938T1 (de) 2001-07-15

Family

ID=24649665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907399T ATE202938T1 (de) 1991-02-22 1992-02-21 Methode zur behandlung des systemischen lupus erythematodes

Country Status (21)

Country Link
US (1) US5078999A (de)
EP (1) EP0572542B9 (de)
KR (1) KR100201517B1 (de)
AT (1) ATE202938T1 (de)
AU (1) AU664545B2 (de)
CA (1) CA2103568A1 (de)
CY (1) CY2305B1 (de)
DE (1) DE69231927T2 (de)
DK (1) DK0572542T3 (de)
ES (1) ES2157901T3 (de)
GR (1) GR3036477T3 (de)
HK (1) HK1011281A1 (de)
HU (1) HUT70489A (de)
IE (1) IE920556A1 (de)
IL (1) IL100904A (de)
MX (1) MX9200727A (de)
NZ (1) NZ241671A (de)
PT (1) PT100145B (de)
SG (1) SG52404A1 (de)
WO (1) WO1992014477A1 (de)
ZA (1) ZA921210B (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
DE69302945T2 (de) 1992-03-27 1996-10-10 American Home Prod 29-Demethoxyrapamycin zur Induktion der Immunosuppression
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
WO1994025022A1 (en) 1993-04-23 1994-11-10 Abbott Laboratories Rapamycin conjugates and antibodies
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
WO2003018573A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin 29-enols
JP2005503395A (ja) 2001-08-22 2005-02-03 ワイス ラパマイシンジアルデヒド
EP1553940B1 (de) 2002-07-30 2008-02-13 Wyeth Parenterale formulierungen mit einem rapamycin hydroxyester
WO2004026280A2 (en) * 2002-09-17 2004-04-01 Wyeth Granulate formulation of the rapamycin ester cci-779
CA2498191C (en) * 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
AU2003301348A1 (en) * 2002-10-18 2004-05-04 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
ES2279407T3 (es) * 2003-04-22 2007-08-16 Wyeth Combinaciones antineoplasicas.
AU2004274026A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
CN1942478A (zh) 2004-04-14 2007-04-04 惠氏公司 用于制备与二羧酸的纳巴霉素42－酯和fk－506 32－酯的方法，用于纳巴霉素配合物的前体和抗体
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US20060210604A1 (en) * 2004-10-04 2006-09-21 Eric Dadey Ocular delivery of polymeric delivery formulations
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
KR20070104908A (ko) * 2005-02-15 2007-10-29 와이어쓰 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물
EP1962839A4 (de) 2005-11-14 2010-08-25 Ariad Pharma Inc Verabreichung von mntor-inhibitoren zur behandlung von krebspatienten
AU2007212271B2 (en) 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
AU2007230964B2 (en) * 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
WO2008022761A2 (en) * 2006-08-22 2008-02-28 Novartis Ag Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders
JP6049160B2 (ja) 2006-09-13 2016-12-27 エリクシアー メディカル コーポレイション 大環状ラクトン化合物およびその使用方法
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
BRPI0919794A2 (pt) * 2008-10-03 2015-12-15 Elixir Medical Corp dispositivo para uso intracorpóreo, e, composto
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
ES2685947T3 (es) 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体

Also Published As

Publication number Publication date
IL100904A0 (en) 1992-11-15
DK0572542T3 (da) 2001-09-17
IE920556A1 (en) 1992-08-26
CA2103568A1 (en) 1992-08-23
PT100145A (pt) 1993-08-31
DE69231927D1 (de) 2001-08-16
AU664545B2 (en) 1995-11-23
CY2305B1 (en) 2003-07-04
MX9200727A (es) 1992-09-01
EP0572542B1 (de) 2001-07-11
EP0572542A1 (de) 1993-12-08
EP0572542A4 (en) 1994-06-01
DE69231927T2 (de) 2001-11-22
KR930703001A (ko) 1993-11-29
ZA921210B (en) 1993-08-19
SG52404A1 (en) 1998-09-28
IL100904A (en) 1995-10-31
GR3036477T3 (en) 2001-11-30
HUT70489A (en) 1995-10-30
ES2157901T3 (es) 2001-09-01
WO1992014477A1 (en) 1992-09-03
EP0572542B9 (de) 2001-11-21
US5078999A (en) 1992-01-07
HK1011281A1 (en) 1999-07-09
AU1469192A (en) 1992-09-15
KR100201517B1 (ko) 1999-06-15
NZ241671A (en) 1997-06-24
PT100145B (pt) 1999-06-30

Similar Documents

Publication Publication Date Title
ATE202938T1 (de) Methode zur behandlung des systemischen lupus erythematodes
EA199800104A1 (ru) Способ лечения диабета
ID30062A (id) Alanog-analog benzopiran tersubstitusi untuk pengobatan radang
EA199900324A1 (ru) Комбинированная терапия для лечения психозов
ATE329911T1 (de) Fsh mimetika zur behandlung von infertilität
DK0555370T3 (da) Metoder og anvendelser for effektive, genetiske suppressorelementer
NO983431L (no) Anti-klöemidler
HUP0004271A2 (hu) Elhízás kezelésére szolgáló, amilint vagy amilin-agonistát tartalmazó készítmények
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE69938179D1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
ES2127396T3 (es) Inhibidores aromaticos de acetilcolinesterasa.
DK1077718T3 (da) Forøgelse af aktiviteten af antibakterielle oxazolidinon-midler ved anvendelse af argininderivater
MX9401175A (es) Inhibidores de la acetilcolinesterasa sililada.
ATE288303T1 (de) Östrogen agonist-antagonist und testosteron enthaltende zusammensetzung zur behandlung abnehmender testosteronspiegel
EA199800764A1 (ru) Способ лечения или предупреждения макулярного отека или возрастной макулярной дистрофии
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DK0996727T3 (da) Obesitas-fænotypefremkaldende gen.
BG30914A3 (en) Incecticide means and method for insects fighting
DE69916013D1 (de) Vorderkammerimplantat zur behandlung des phaken auges
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
DE69914200D1 (de) Aminoiminochinon und aminochinon alkaloid verbindungen als caspase inhibitoren
ES1019098Y (es) Camara de aireacion y amortizacion para calzados.
AR021749A1 (es) Uso de derivados de tiazolidinediona para el tratamiento o prevencion de cataratas.
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
DK1299102T3 (da) Anvendelse af riluzol eller salte deraf til forebyggelse og behandling af adrenoleukodystrofi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee